Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock) (RESCUE-Shock)

Resuscitative Endocrinology: (RESCUE - Shock): A Phase II Trial to Evaluate the Effects of Single Dose Intravenous Premarin for Treatment of Patients With Hemorrhagic Shock

Based on encouraging results from animal studies, the investigators hypothesize that early administration of IV Premarin® in patients with hemorrhagic shock will safely reduce secondary injury, and improve survival.

Study Overview

• Status: Completed
• Conditions: Hemorrhagic Shock
• Intervention / Treatment: Drug: Premarin IV; Drug: Placebo

Detailed Description

Annually in the United States, approximately 30 million people require treatment for traumatic injuries in emergency departments. Two million of these patients require hospitalization, with several hundred thousand ultimately dying, often due to extreme blood loss. Importantly, these traumatic injuries are the leading cause of death and disability for children and young adults under the age of 44, with the total cost of trauma in the U.S. approaching $260 billion each year.

Despite advances in pre-hospital care, early resuscitation, surgical interventions and intensive care monitoring aimed at the primary traumatic injury, many survivors never recover. A significant cause of this mortality and morbidity is thought due to potentially preventable secondary injury, namely oxidant injury, inflammation, and apoptosis beginning in the first few hours after the severe traumatic event.

In spite of the current bleak outlook for many of these patients, a series of animal investigations have uncovered a promising solution to the problem of the secondary injury seen in hemorrhagic shock and other similar processes, namely the early administration of estrogen, a strong anti-oxidant, anti-inflammatory and anti-apoptotic compound.

Based on encouraging results from animal studies, the investigators hypothesize that early administration of IV Premarin® in patients with hemorrhagic shock will safely reduce secondary injury, and improve survival.

• Study Type: Interventional
• Enrollment (Actual): 50
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Texas
    • Dallas, Texas, United States, 75246
      • Baylor University Medical Center
    • Dallas, Texas, United States, 75235
      • Parkland Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age≥ 18 yrs or < 50 yrs
2. Blunt or penetrating trauma leading to presumed hemorrhagic shock
3. Pre-hospital or ED systolic blood pressure < 90
4. Receiving medical treatment in the Emergency Department (ED) of Parkland Hospital or Baylor University Medical Center Emergency Department, Level I Trauma Centers in Dallas, Texas

Exclusion Criteria:

1. Those who would receive the study drug > 120 minutes after the traumatic event
2. Time of injury is unknown
3. Known indication for IV estrogen
4. Known contraindication for estrogen
5. Estimated age <18 or > 50 years
6. Cardiopulmonary Resuscitation (CPR) prior to randomization
7. Known incarceration
8. Severe hypothermia (suspected T < 28° C)
9. Drowning or asphyxia due to hanging
10. Burns total body surface area (TBSA) > 20%
11. Isolated penetrating injury to the head
12. Known inclusion in another interventional trial related to this traumatic event prior to randomization
13. Known legal do not resuscitate (DNR) orders in place prior to randomization
14. Recognized spinal cord injury prior to study drug administration

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Premarin IV; Patients who were randomized to receive a single dose of 0.5 mg/kg Premarin® IV.	Drug: Premarin IV; One time dose of Premarin IV; Other Names: Estrogen IV
PLACEBO_COMPARATOR: Placebo; Patients who were randomized to receive a single dose of 0.5 mg/kg placebo. Due of the faint yellow color of the reconstituted Premarin®, the placebo dose will be prepared with 0.14 ml of Vial 1 of Infuvite Adult Multivitamin and 14 ml of sterile water to generate a similar color and volume. This aliquot will be used only for those study patients who are randomized to the placebo arm. The placebo volume will be approximately equal to the volume which the patient would have received had the patient been randomized to the Premarin arm Considering the small amount of IV multivitamin needed for fluid tinting, it is not expected that the IV multivitamin will have any effect on patients with hemorrhagic shock.	Drug: Placebo; One time dose of placebo.; Other Names: Infuvite Multivitamin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Survival	Survival is defined as the number of patients who were discharged from the hospital alive prior to 28 days post injury or the number of patients still alive in the hospital 28 days post injury. The trial examines the rate of enrolled patients on each arm who survived to 28 days.	28 Days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Acute Respiratory Distress Syndrome (ARDS) Free Survival	ARDS is a life-threatening condition characterized by inflammation of the lungs. The trial measures the number of days alive and without ARDS within 28 days post injury. Patients who die within 28 days are given value of 0, similarly, patients who live 28 days but have ARDS for all 28 days. A higher score (greater days) indicates better prognosis. Exudative stage is 0-6 days, proliferative stage is 7-10 days, Fibrotic stage is >10-14 days.	28 days

Collaborators and Investigators

• Sponsor: University of Texas Southwestern Medical Center
• Collaborators: University of Washington; Resuscitation Outcomes Consortium
• Investigators: Study Director: Rob Schmickers, University of Washington

Study record dates

Study Major Dates

• Study Start: July 1, 2009
• Primary Completion (ACTUAL): January 1, 2012
• Study Completion (ACTUAL): May 1, 2012

Study Registration Dates

• First Submitted: July 19, 2009
• First Submitted That Met QC Criteria: September 4, 2009
• First Posted (ESTIMATE): September 9, 2009

Study Record Updates

• Last Update Posted (ACTUAL): March 19, 2020
• Last Update Submitted That Met QC Criteria: March 17, 2020
• Last Verified: March 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Hemorrhage; Shock; Shock, Hemorrhagic; Physiological Effects of Drugs; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Estrogens; Estrogens, Conjugated (USP)
• Other Study ID Numbers: RESCUE - Shock

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO